Swiss Life Asset Management Ltd Raises Holdings in Eli Lilly and Company $LLY

Swiss Life Asset Management Ltd raised its stake in Eli Lilly and Company (NYSE:LLY) by 5.1% during the third quarter, Holdings Channel.com reports. The firm owned 301,751 shares of the company’s stock after purchasing an additional 14,566 shares during the quarter. Eli Lilly and Company accounts for about 1.2% of Swiss Life Asset Management Ltd’s portfolio, making the stock its 13th largest position. Swiss Life Asset Management Ltd’s holdings in Eli Lilly and Company were worth $230,236,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Innova Wealth Partners increased its stake in shares of Eli Lilly and Company by 14.8% during the third quarter. Innova Wealth Partners now owns 1,260 shares of the company’s stock worth $961,000 after buying an additional 162 shares during the period. Stillwater Wealth Management Group purchased a new position in Eli Lilly and Company in the third quarter worth approximately $3,928,000. Tevis Investment Management grew its holdings in Eli Lilly and Company by 42.0% during the 3rd quarter. Tevis Investment Management now owns 1,861 shares of the company’s stock worth $1,420,000 after acquiring an additional 550 shares in the last quarter. PCG Asset Management LLC grew its holdings in Eli Lilly and Company by 5.4% during the 3rd quarter. PCG Asset Management LLC now owns 465 shares of the company’s stock worth $355,000 after acquiring an additional 24 shares in the last quarter. Finally, Payne Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $216,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of a number of analyst reports. Cantor Fitzgerald raised their price objective on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,221.44.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: TRANSCEND‑T2D‑1 Phase 3 topline: retatrutide produced ~16.8% weight loss and meaningful A1C reductions at 40 weeks — a potential category‑defining asset if approved and commercialized. Lilly PRNewswire
• Positive Sentiment: Analyst stance: some firms (e.g., RBC) still view retatrutide as a key multi‑year growth driver for LLY, underscoring upside to revenue/earnings expectations if safety and pricing look favorable over time. RBC Capital View
• Positive Sentiment: Pipeline breadth and capacity: Lilly is expanding GI/IBD and immunology programs (master IBD study, mirikizumab work) and investing in manufacturing/capacity (Indianapolis upgrades; new PA plant), supporting long‑term commercial execution. TipRanks IBD Study
• Neutral Sentiment: Widespread press coverage highlights retatrutide’s efficacy (reports range ~15–17% weight loss), which boosts visibility but doesn’t change regulatory/timing risk. Forbes Coverage
• Neutral Sentiment: Insider/congressional disclosure data show purchases by a lawmaker, a signal some investors watch but not a market mover by itself. MarketBeat Congress Trades
• Negative Sentiment: New safety note: separate reporting flagged an unusual skin reaction in retatrutide data that could give prescribers pause and complicate adoption vs competitors. Safety signals raise approval/labeling and marketing uncertainty. Proactive: Skin Concern
• Negative Sentiment: Analyst downgrades & pricing concerns: HSBC and others cut ratings/targets citing U.S. pricing pressure, rising competition and compounded risks from rivals (and tirzepatide), prompting near‑term selloffs. HSBC Downgrade Coverage
• Negative Sentiment: Competitive risk: Novo Nordisk won FDA clearance for a higher‑dose Wegovy (7.2 mg), intensifying head‑to‑head competition in obesity and potentially pressuring pricing and market share. Blockonomi: Wegovy Dose

Eli Lilly and Company Stock Performance

NYSE LLY opened at $916.94 on Friday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The company has a market capitalization of $866.34 billion, a PE ratio of 39.95, a P/E/G ratio of 1.07 and a beta of 0.40. The company has a fifty day moving average of $1,026.34 and a two-hundred day moving average of $954.98.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the previous year, the firm earned $5.32 earnings per share. The business’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.